Wegovy Titration for a 14-Year-Old
For a 14-year-old with obesity, initiate Wegovy (semaglutide) at 0.25 mg subcutaneously once weekly for 4 weeks, then escalate the dose every 4 weeks (0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg) until reaching the maintenance dose of 2.4 mg weekly. 1
FDA-Approved Dosing Schedule for Adolescents
The FDA label explicitly states that the maintenance dosage of Wegovy in pediatric patients aged 12 years and older is 2.4 mg once weekly 1. This is the same target dose used in adults, supported by the STEP TEENS trial which demonstrated significant efficacy in adolescents 2.
Standard Titration Protocol
The titration schedule is:
- Week 1-4: 0.25 mg once weekly
- Week 5-8: 0.5 mg once weekly
- Week 9-12: 1.0 mg once weekly
- Week 13-16: 1.7 mg once weekly
- Week 17 onward: 2.4 mg (maintenance dose)
This gradual 4-week escalation minimizes gastrointestinal adverse effects (nausea, vomiting, diarrhea), which occur more frequently with faster titration 3.
Alternative Maintenance Dose Option
Recent FDA approval (November 2024) now permits 1.7 mg weekly as an alternative maintenance dose for adolescents 4. Modeling studies demonstrated that 1.7 mg provides comparable exposure and efficacy to 2.4 mg in adolescents, with mean BMI reduction of -15.2% versus -17.4% respectively—both significantly superior to placebo 4. This lower dose may be appropriate for adolescents who:
- Experience intolerable side effects at 2.4 mg
- Achieve adequate weight loss response at 1.7 mg
- Have tolerability concerns that would otherwise lead to discontinuation
Clinical Considerations Specific to Adolescents
Pre-Treatment Assessment
- BMI requirement: Must be ≥95th percentile for age and sex (obesity) 5
- Body weight: Should be ≥60 kg per approval criteria 6
- Type 2 diabetes screening: If present, monitor blood glucose before starting and throughout treatment 1
Monitoring During Titration
Adolescents require closer monitoring than adults for specific adverse events 1:
- Cholelithiasis/cholecystitis: Higher incidence in adolescents (5 patients [4%] in STEP TEENS vs. lower rates in adults) 1, 2
- Hypotension, rash, urticaria: More common in pediatric patients 1
- Suicidal ideation: Monitor for depression or suicidal thoughts; discontinue if symptoms develop 1
Dose Adjustment Flexibility
Clinical judgment should guide titration speed 3. If gastrointestinal side effects are severe:
- Extend the duration at current dose beyond 4 weeks before escalating
- Some patients achieve adequate response at submaximal doses and can remain on that dose long-term 3
Missed Doses
- ≤2 consecutive doses missed: Resume at same dose if previously well-tolerated 3
- >2 consecutive doses missed: Consider lowering next dose 3
- ≥3 consecutive doses missed: Restart titration schedule 3
Efficacy Data in Adolescents
The STEP TEENS trial (N=201, ages 12-<18 years) demonstrated 2:
- Mean BMI reduction: -16.1% with semaglutide 2.4 mg vs. +0.6% with placebo at 68 weeks
- ≥5% weight loss: 73% of semaglutide group vs. 18% of placebo group
- Cardiometabolic improvements: Reductions in waist circumference, HbA1c, lipids (except HDL), and ALT
Safety Profile in Adolescents
Gastrointestinal adverse events are the most common (62% vs. 42% with placebo) 2:
- Nausea, vomiting, diarrhea, constipation, abdominal pain
- These are dose-dependent and typically diminish with continued treatment
Serious adverse events occurred in 11% of adolescents (vs. 9% placebo) 2. The gradual titration schedule is specifically designed to minimize these effects 3.
Contraindications
Do not prescribe Wegovy if the adolescent has 1:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide
Administration Details
- Route: Subcutaneous injection in abdomen, thigh, or upper arm 1
- Timing: Same day each week, any time of day, with or without meals 1
- Lifestyle intervention: Must be combined with reduced-calorie diet and increased physical activity 1
Long-Term Considerations
Limited long-term safety data exist for adolescents 7. The STEP TEENS trial duration was 68 weeks, so risks beyond this timeframe remain uncertain, particularly regarding cholelithiasis, pancreatitis, and effects on growth/development 7. However, the substantial BMI reduction and cardiometabolic benefits support use when obesity-related complications are present.